spacer
The Healthcare Sales & Marketing Network celebrates 27 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  glucagon-like peptide 

 HSMN NewsFeed - 6 Nov 2023
NeuroBo Pharmaceuticals Strengthens Board of Directors with the Appointment of James P. Tursi, M.D.
Biopharmaceuticals Personnel
 HSMN NewsFeed - 12 May 2023
NeuroBo Pharmaceuticals, Inc. Appoints Pharmaceutical Industry Executive, Mark A. Glickman, to its Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 18 Jan 2023
NeuroBo Pharmaceuticals Appoints Joseph Hooker as Interim Chief Executive Officer and President
Biopharmaceuticals Personnel
 HSMN NewsFeed - 29 Jul 2021
Oramed Pharmaceuticals Appoints Chief Commercial Officer
Biopharmaceuticals Drug Delivery Personnel
 HSMN NewsFeed - 19 Mar 2021
Oramed Forms a Joint Venture, Oravax Medical Inc., for the Development of Novel Oral COVID-19 Vaccines
Biopharmaceuticals
 HSMN NewsFeed - 12 May 2020
Kriya Therapeutics announces $80 million Series A financing to advance gene therapies for highly prevalent serious diseases
Biopharmaceuticals Venture Capital Personnel
 HSMN NewsFeed - 26 Feb 2020
Oramed Reports Positive Results in the Final Cohort of Its Phase 2b Oral Insulin Trial
Biopharmaceuticals Drug Delivery Endocrinology
 HSMN NewsFeed - 30 Jan 2020
Oramed Appoints Dr. Julio Rosenstock to Its Scientific Advisory Board
Biopharmaceuticals Drug Delivery Personnel
 HSMN NewsFeed - 23 Jan 2020
Oramed Elects Dr. Alexander Fleming to Scientific Advisory Board
Biopharmaceuticals Drug Delivery Personnel
 HSMN NewsFeed - 21 Jan 2020
Oramed Appoints Dr. Jay Skyler to Scientific Advisory Board
Biopharmaceuticals Drug Delivery Personnel
 HSMN NewsFeed - 20 Sep 2019
CHMP Issues Positive Opinion to Expand Trulicity(R) (dulaglutide) Label to Include Results from REWIND Cardiovascular Outcomes Trial
Biopharmaceuticals Endocrinology Cardiology Regulatory
 HSMN NewsFeed - 17 May 2019
U.S. FDA Approves GATTEX(R) (teduglutide) for Children 1 Year of Age and Older With Short Bowel Syndrome (SBS)
Biopharmaceuticals Gastroenterology FDA
 HSMN NewsFeed - 26 Feb 2018
New Data Show Lilly's Trulicity(R) (dulaglutide) in Combination with an SGLT-2 Inhibitor Improves Blood Sugar Control in People with Type 2 Diabetes
Biopharmaceuticals Endocrinology
 HSMN NewsFeed - 7 Jul 2016
Shire Receives Extension of Market Authorization in Europe for Revestive(R) (Teduglutide) for the Treatment of Paediatric Patients with Short Bowel Syndrome (SBS)
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 11 Mar 2014
Lumena Pharmaceuticals Raises $45 Million in Series B Financing
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 3 Mar 2014
U.S. FDA Approves Bydureon(R) Pen (exenatide extended-release for injectable suspension) for Once-Weekly Treatment of Adults with Type 2 Diabetes
Biopharmaceuticals Drug Delivery Endocrinology FDA
 HSMN NewsFeed - 26 Jul 2013
Intarcia Therapeutics Appoints Gino Santini To Its Board Of Directors
Biopharmaceuticals Drug Delivery Personnel
 HSMN NewsFeed - 17 Jul 2013
Intarcia Therapeutics Appoints Dr. Eddie Li Vice President and Global Head of Regulatory Affairs
Biopharmaceuticals Drug Delivery Personnel
 HSMN NewsFeed - 21 Dec 2012
FDA Approves Gattex(R) (teduglutide [rDNA Origin]) for Injection for the Treatment of Adult Short Bowel Syndrome
Biopharmaceuticals Gastroenterology FDA
 HSMN NewsFeed - 4 Sep 2012
Revestive(R) (teduglutide) Receives European Marketing Authorization for the Treatment of Adults with Short Bowel Syndrome (SBS)
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 22 Jun 2012
Takeda Receives Positive CHMP Opinion for Teduglutide (Revestive(R)) for Patients with Short Bowel Syndrome
Biopharmaceuticals Gastroenterology Regulatory
 HSMN NewsFeed - 23 Mar 2012
BYETTA(R) Approved for Use with Basal Insulin in Europe
Biopharmaceuticals Endocrinology Regulatory
 HSMN NewsFeed - 8 Nov 2011
Lilly and Amylin Mutually Agree to End Diabetes Alliance and Transition Exenatide Responsibility to Amylin
Biopharmaceuticals
 HSMN NewsFeed - 21 Jun 2011
Bydureon Receives Marketing Authorization in Europe
Biopharmaceuticals Endocrinology Regulatory
 HSMN NewsFeed - 16 May 2011
Lilly Provides Its Perspective in Response to Amylin Lawsuit
Biopharmaceuticals Litigation
 HSMN NewsFeed - 16 May 2011
Lilly Provides Statement in Response to Amylin Lawsuit
Biopharmaceuticals Litigation
 HSMN NewsFeed - 16 May 2011
Amylin Pharmaceuticals Files Suit Against Eli Lilly
Biopharmaceuticals Litigation
 HSMN NewsFeed - 15 Apr 2011
BYDUREON Recommended for Approval in Europe
Biopharmaceuticals Endocrinology Regulatory
 HSMN NewsFeed - 31 Jan 2011
GATTEX(R) (teduglutide) Meets Primary Efficacy Endpoint in Phase 3 Pivotal Study in Patients with Adult Short Bowel Syndrome
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 29 Apr 2010
Ipsen's Partner Roche Announces That Taspoglutide Meets Its Primary Endpoint in a Key Phase III Clinical Trial
Biopharmaceuticals Endocrinology
 HSMN NewsFeed - 15 Mar 2010
Amylin, Lilly and Alkermes Receive Complete Response Letter From FDA for Exenatide Once Weekly Submission
Biopharmaceuticals
 HSMN NewsFeed - 26 Jan 2010
Novo Nordisk's Victoza(R) Receives FDA Approval for Adults With Type 2 Diabetes
Biopharmaceuticals Endocrinology FDA
 HSMN NewsFeed - 2 Apr 2009
Update on FDA Advisory Committee Meeting on Liraglutide for the Treatment of Type 2 Diabetes
Biopharmaceuticals Endocrinology FDA
 HSMN NewsFeed - 17 Feb 2009
GSK Initiates Phase III Programme for Novel Type 2 Diabetes Medication, Syncria(R) (albiglutide)
Biopharmaceuticals Endocrinology
 HSMN NewsFeed - 27 Nov 2008
Helsinn Healthcare and Zealand Pharma Sign a Partnering Agreement for ZP1846, a Novel GLP-2 Agonist
Biopharmaceuticals Oncology
 HSMN NewsFeed - 10 Jun 2008
Roche Moves Investigational Diabetes Drug, Taspoglutide, Into Phase III Clinical Trials
Biopharmaceuticals Endocrinology
 HSMN NewsFeed - 19 May 2008
Phase 3 GATTEX(TM) Results Presented at Annual Digestive Disease Week Congress Highlight Potential New Treatment in Short Bowel Syndrome
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 17 Mar 2008
NPS Reports Successful GATTEX(TM) Extension Study
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 6 Dec 2007
Monotherapy BYETTA(R) Showed Significant Improvement in Glucose Control and Weight Loss in Adults with Type 2 Diabetes
Biopharmaceuticals Endocrinology
 HSMN NewsFeed - 2 Oct 2007
Isis Earns $5 Million Milestone Payment From Ortho-McNeil, Inc. for Initiation of Phase 1 Study of ISIS 325568
Biopharmaceuticals Endocrinology
 HSMN NewsFeed - 26 Sep 2007
NPS Pharmaceuticals and Nycomed Announce Licensing Agreement for GATTEX(TM) in Territories Outside North America
Biopharmaceuticals Gastroenterology Licensing
 HSMN NewsFeed - 18 Sep 2007
One-Year Data Showed Investigational Use of Initial Combination Therapy with JANUVIA(TM) (sitagliptin) and Metformin Significantly Improved Blood Sugar Control in Patients with Type 2 Diabetes Compared to Metformin Alone
Biopharmaceuticals Endocrinology
 HSMN NewsFeed - 6 Jun 2007
Amgen to Acquire Alantos Pharmaceuticals, a Private Biotechnology Company in Cambridge, Massachusetts
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 20 Feb 2007
New Storage Instructions Approved for BYETTA(R)
Biopharmaceuticals Endocrinology FDA
 HSMN NewsFeed - 3 Jan 2007
FDA Approves BYETTA(R) (exenatide) Injection for Expanded Combination Use
Biopharmaceuticals Endocrinology FDA
 HSMN NewsFeed - 22 Dec 2006
FDA Approves BYETTA(R) (exenatide) Injection for Expanded Combination Use
Biopharmaceuticals Endocrinology FDA
 HSMN NewsFeed - 21 Nov 2006
BYETTA(R) (exenatide) Approved for Treatment of Type 2 Diabetes by European Commission
Biopharmaceuticals Endocrinology Regulatory
 HSMN NewsFeed - 21 Sep 2006
Exenatide Receives Positive Opinion From the European Committee for Medicinal Products for Human Use for the Treatment of Type 2 Diabetes
Biopharmaceuticals Endocrinology
 HSMN NewsFeed - 14 Sep 2006
Study Shows Exenatide Improves Blood Sugar Levels as Effectively as Biphasic Insulin Aspart
Biopharmaceuticals Endocrinology
Return to NewsFeed  

 Additional items found! 23

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 23 additional stories matching:
glucagon-like peptide
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.